You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Breast cancer

Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer

  • Technology appraisal guidance
  • Reference number: TA503
  • Published:  31 January 2018
  • Guidance
  • Tools and resources
  • Information for the public
  • History

On this page

  1. Expected publication
  2. Final appraisal determination: 1
  3. Draft guidance: 1
  4. Invitation to participate

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 231 KB)

    Published:
    31 January 2018

Final appraisal determination: 1

  • Final appraisal determination: 1

  • Committee papers (PDF 3.66 MB)

    Published:
    14 December 2017
  • Final appraisal determination document (PDF 316 KB)

    Published:
    14 December 2017
  • Public committee slides (PDF 257 KB)

    Published:
    14 December 2017

Draft guidance: 1

  • Draft guidance: 1

  • Public committee slides clinical presentation slides (PowerPoint 986 KB)

    Published:
    01 September 2017
  • Public committee slides cost presentation slides (PowerPoint 132 KB)

    Published:
    01 September 2017
  • Committee papers (PDF 21.09 MB)

    Published:
    01 September 2017
  • Appraisal consultation document (PDF 327 KB)

    Published:
    11 September 2017

Invitation to participate

  • Final scope (PDF 239 KB)

    Published:
    15 March 2017
  • Final matrix (PDF 340 KB)

    Published:
    15 March 2017
  • NICE's response to comments on the draft scope and provisional matrix (PDF 289 KB)

    Published:
    15 March 2017
  • Equality impact assessment (Scoping) (PDF 174 KB)

    Published:
    15 March 2017
Back to top